alpha-chymotrypsin and Carcinoma--Non-Small-Cell-Lung

alpha-chymotrypsin has been researched along with Carcinoma--Non-Small-Cell-Lung* in 2 studies

Trials

1 trial(s) available for alpha-chymotrypsin and Carcinoma--Non-Small-Cell-Lung

ArticleYear
Micronuclei evaluation of reduction in neoadjuvant chemotherapy related acute toxicity in locally advanced lung cancer: an indian experience.
    The Journal of the Association of Physicians of India, 2006, Volume: 54

    Lung cancer is the most common cancer in the world accounting for 17.6% cancers worldwide. The AAR i n I ndian population varies f r om 0.98-15.55. The aim of t he present study was to analyze areduction in neoadjuvant chemotherapy related acute toxicity in locally advanced lung cancer (stage IIIA and III B) using Wobe Mugos E and its evaluation using micronuclei as a cytogenetic marker. Micronuclei, which are cytoplasmic fragments of DNA, have been used as a biological dosimeter to assess DNA damage.. Fourty patients of locally advanced NSCLC were randomized into two study groups between 2001-2003. One group received neoadjuvant chemotherapy using Cisplatin and Etoposide. The other group received neoadjuvant chemotherapy using Cisplatin and Etoposide along with Wobe Mugos E which is a proteolytic enzyme preparation. A study of micronuclei frequency was done pre and post chemotherapy in both groups.. Thirty eight patients were available for final evaluation. Anemia was the most common hematological toxicity observed. Nausea and vomiting were the most common non -hematological toxicity seen. Wobe Mugos E was found to reduce the incidence of leucopenia (p = 0.005), nausea (p=0.004), vomiting (p= 0.003), sensory neuropathy (p = 0.032) and treatment related depression (p= 0.005). A reduction in micronuclei was seen in patients in patients on Wobe Mugos E. (p =0.01).. Neo-adjuvant chemotherapy related acute toxicity is a major problem in patients with advanced lung cancer. A reduction in micronuclei frequency shows Wobe Mugos E to be effective in reducing chemotherapy related acute toxicity.

    Topics: Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Chymotrypsin; Drug Combinations; Female; Humans; India; Lung Neoplasms; Male; Micronuclei, Chromosome-Defective; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Papain; Trypsin

2006

Other Studies

1 other study(ies) available for alpha-chymotrypsin and Carcinoma--Non-Small-Cell-Lung

ArticleYear
Beta-Catenin in Non-Small Cells Lung Cancer and Its Association with Proteasomes.
    Bulletin of experimental biology and medicine, 2020, Volume: 168, Issue:5

    We analyzed the content of β-catenin fractions and activity and content of proteasomes in the tissues of patients with non-small cells lung cancer. The content of β-catenin fractions was elevated and proteasome-dependent proteolysis in the tumor tissue was enhanced in comparison with the corresponding unchanged lung tissue. A negative regression relationship of caspase-like activity of proteasomes and a positive correlation between the content of proteasomes and both fractions of β-catenin were found. We hypothesize that proteasomes are involved in the degradation of β-catenin due to caspase-like activity.

    Topics: beta Catenin; Carcinoma, Non-Small-Cell Lung; Caspases; Chymotrypsin; Female; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Proteasome Endopeptidase Complex; Wnt Signaling Pathway

2020